OR WAIT null SECS
Amgen and Syngene International have extended their research collaboration to 2026.
Syngene International, a research, development, and manufacturing services company, announced on Dec. 16, 2021 that the company and Amgen have extended their long-standing multi-discipline research collaboration to the end of 2026.
The scope of the collaboration includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. Under the extended contract, Syngene will build and operate a dedicated laboratory, which will enable the acceleration of R&D projects. Syngene currently operates the existing Syngene Amgen R&D Center (SARC) under the companies’ original collaboration deal.
SARC was established in 2016 and was expanded in 2017. The center currently consists of 60,000 ft2 of floor space. A dedicated team of multi-disciplinary Syngene scientists are working closely with Amgen researchers on the discovery and development of innovative medicines.
"While SARC was established in 2016, our collaboration with Amgen dates back to 2012. During this time, we have partnered on research and development to address some of the most serious diseases in the world. We have progressively expanded our areas of collaboration, co-authored research papers on novel science, and supported the advancement of multiple development projects, while adhering to global standards of quality and safety,” said Jonathan Hunt, CEO and managing director, Syngene International, in a company press release.
“Amgen is pleased with the success of the long-standing collaboration with Syngene t“Amgen is pleased with the success of the long-standing collaboration with Syngene that has contributed to the advancement of a number of molecules into clinical trials,” said Margaret Chu-Moyer, vice-president of Research and head of Chemistry, Characterization & Technology at Amgen, in the press release. “We look forward to continuing to work together with the shared goal of addressing serious disease for patients in need.”
Source: Syngene International